Earnings Insights · CVS · Q3 FY2026

CVS Health Q3 2026 Earnings: CVS Plans Separation as Aetna Margin Recovery Lifts Guidance

By AlgovestIQ ResearchPublished

Share

Read CVS Health’s results announcement (Form 8-K, filed Nov 4, 2026)

Key earnings findings

CVS Health (CVS) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. CVS Health reported Q3 FY2026 revenue of $108.40B against the $104.72B analyst estimate, a 3.5% beat, and EPS of $2.09 against the $1.65 analyst estimate, a 26.7% beat.
  2. CVS closed at $79.96 on Nov 4, 2026, down 12.5% from $91.41 on Nov 3, 2026, the last close before the results were released.
  3. CVS Health reported third-quarter revenue of $108.4B, up 5.4% year over year, with GAAP diluted EPS of $1.68 and adjusted EPS of $2.09.

Sources: CVS Health results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did CVS Health beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$108.40B
$104.72B
+3.5%
EPS
$2.09
$1.65
+26.7%
  • EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
  • Revenue surprise across the last 8 reported quarters has ranged from 0.6% to 6.1%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

CVS Health reported third-quarter revenue of $108.4B, up 5.4% year over year, with GAAP diluted EPS of $1.68 and adjusted EPS of $2.09. The underlying quarter was stronger than the headline revenue growth alone suggests: Aetna’s medical-cost performance improved, retail pharmacy profit rose despite lower revenue, and CVS raised its 2026 earnings and cash-flow outlook.

The larger development, however, was strategic. CVS plans to separate into two publicly traded companies by the first half of 2028, subject to customary approvals: a health solutions company retaining Aetna, Caremark, specialty pharmacy and care-delivery assets, and a CVS Pharmacy company containing retail stores, mail order, MinuteClinic and Health100.

Earnings Snapshot

MetricReportedChange
Total revenue$108.4BUp 5.4%
GAAP operating income$3.6BFrom a $3.2B loss
Adjusted operating income$4.2BUp 21.2%
GAAP diluted EPS$1.68From $(3.13)
Adjusted EPS$2.09Up from $1.60
Health Care Benefits revenue$36.9BUp 2.4%
Health Care Benefits adjusted operating income$912MUp from $314M
Health Care Benefits medical benefit ratio91.3%Down 150 bps
Health Services revenue$54.0BUp 9.5%
Health Services adjusted operating income$2.1BUp 2.7%
Pharmacy & Consumer Wellness revenue$35.5BDown 2.0%
Pharmacy & Consumer Wellness adjusted operating income$1.6BUp 10.6%
Year-to-date operating cash flow$15.3BUp from $7.2B

The Bigger Story

CVS is separating its integrated model at a point when its operating performance and balance sheet have improved. The remaining CVS Health company will retain the insurance, pharmacy benefit management, specialty pharmacy, and value-based care assets that management believes are most relevant to controlling medical and pharmacy costs. The CVS Pharmacy company will include roughly 9,000 retail pharmacies, mail order, MinuteClinic and the Health100 consumer-engagement platform.

Management expects the transaction to be tax-free for U.S. federal income tax purposes and completed in the first half of 2028. Current shareholders are expected to own shares in both companies.

The strategic case rests on greater focus, more tailored capital allocation and simpler operating structures. But the separation also introduces execution questions. CVS will need to preserve commercially important relationships between Caremark and CVS Pharmacy, including pharmacy fulfillment and consumer-facing pharmacy programs, through long-term agreements rather than common ownership.

Management said both companies are expected to have investment-grade balance sheets and strong free-cash-flow profiles. Specific capital structures, separation costs and any ongoing dis-synergies have not yet been disclosed. CVS expects the strategic benefits to outweigh stranded costs and said it intends to offset recurring public-company and separation-related expenses over time.

Revenue and Operating Performance

Revenue growth was led by Health Services, where sales increased 9.5% to $54.0B. Pharmacy drug mix and brand inflation drove most of the increase, partly offset by continued price improvements for pharmacy-benefit clients. Pharmacy claims processed rose 1.3% on a 30-day equivalent basis to 481.7 million.

That revenue growth translated into only a 2.7% increase in adjusted operating income, to $2.1B. The segment benefited from purchasing economics and drug mix, but client pricing concessions continued to limit profit conversion. Health Services adjusted operating margin declined to 3.9% from 4.2% a year earlier.

Management said pharmacy-services performance, including its 340B and rebate-guarantee businesses, was in line with expectations. Specialty pharmacy remained a source of strength, while health care delivery performance also tracked management’s plan.

Health Care Benefits revenue increased 2.4% to $36.9B. Government business growth more than offset a decline related to CVS’s 2026 exit from the individual exchange business. Government premium revenue rose 8.2% to $28.1B, while commercial premium revenue fell 16.9% to $6.5B.

Total medical membership was 26.1 million at September 30, down from 26.7 million a year earlier but broadly stable sequentially. The year-over-year decline largely reflects lower commercial enrollment, while Medicare Advantage membership was essentially flat at 4.2 million.

Pharmacy & Consumer Wellness revenue declined 2.0% to $35.5B. Regulatory-related price reductions on certain drugs, generic drug introductions and reimbursement pressure outweighed higher prescription volumes, favorable drug mix and brand inflation. The acquired Rite Aid prescription files also added volume.

Retail prescription volume rose 3.9% at comparable stores, while prescriptions filled rose 1.9% on a 30-day equivalent basis to 470.0 million. Management said GLP-1 prescription volume increased 23% during the quarter, reflecting efforts to improve patient access and affordability.

The retail segment’s same-store sales declined 0.6%, including a 0.6% decline in both pharmacy and front-store sales. That gap between prescription demand and reported sales reinforces the impact of reimbursement and drug-price dynamics on the retail model.

Profitability and Margins

The sharp swing in GAAP earnings largely reflects the absence of a $5.7B goodwill impairment charge recorded in the third quarter of 2025 related to the Health Care Delivery reporting unit. CVS reported GAAP operating income of $3.6B, versus a $3.2B operating loss a year ago.

Adjusted results provide a clearer view of the quarter’s operating improvement. Adjusted operating income increased 21.2% to $4.2B, while adjusted EPS rose 31% to $2.09 from $1.60.

The strongest improvement came from Health Care Benefits. Adjusted operating income increased to $912M from $314M, and adjusted operating margin rose to 2.5% from 0.9%. The medical benefit ratio improved 150 basis points to 91.3%, driven by better underlying performance in the Government business, particularly Medicare.

Management said elevated medical-cost trends remain above historical levels but were broadly in line with expectations. Medicare performance modestly exceeded internal expectations, supported by medical-cost management and disciplined pricing. CVS also said it remains confident in the adequacy of its reserves.

The segment’s year-to-date performance also benefited from $1.3B of favorable prior-year health-care cost development. That development supported earnings through the first nine months, although the core quarterly MBR improvement is the more important indicator of Aetna’s margin-recovery progress.

Retail pharmacy delivered the clearest example of earnings growth without revenue growth. Pharmacy & Consumer Wellness adjusted operating income rose 10.6% to $1.6B, and adjusted operating margin expanded to 4.6% from 4.1%. Core pharmacy strength and Rite Aid asset contributions more than offset business investments and weaker consumer dynamics.

Demand, Customers and Pricing

The central demand signal was resilient prescription utilization. Health Services claims increased 1.3%, while retail prescription volume grew 3.9% at comparable locations. CVS’s retail results suggest prescription demand remains supportive even as reimbursement pressure, generic competition and drug-price reductions constrain reported revenue.

In Health Services, management expects health-plan client membership attrition and a less robust selling season to weigh on 2027 results. It characterized some expected membership declines as strategic decisions by health-plan customers rather than a reflection of Caremark’s market offering.

Management expects 340B earnings to decline year over year in 2027 and to largely stabilize by the end of that year. CVS expects Health Services to return to growth thereafter, with specialty pharmacy strength and improving care-delivery profitability providing partial offsets.

For Aetna’s Medicare Advantage business, management said it has used benefit, geographic, product, provider-network and pricing changes to restore profitability. The company expects modest growth in selected Medicare markets during 2027, while maintaining a cautious view of industry medical-cost trends.

What is CVS Health’s guidance for 2026?

CVS raised its full-year 2026 outlook. Management now expects:

  • Total revenue of at least $420.0B
  • GAAP diluted EPS of at least $6.98
  • Adjusted EPS of at least $8.20
  • Operating cash flow of at least $15.5B
  • Enterprise adjusted operating income of at least $17.05B

The adjusted EPS outlook was raised from a prior range of $7.90 to $8.10. The operating-cash-flow outlook increased from at least $11.5B.

At the segment level, management expects Health Care Benefits adjusted operating income of at least $5.4B, up $200M from the midpoint of its previous outlook. Full-year medical benefit ratio is expected to be in the lower half of the previously stated 89.75%, plus or minus 25 basis point, range.

Pharmacy & Consumer Wellness adjusted operating income is expected to reach $6.5B, up $100M from the prior outlook and representing nearly 8% growth from 2025. CVS reiterated its prior 2026 Health Services adjusted operating income outlook.

For 2027, management set an initial adjusted EPS expectation of at least $8.65, representing approximately 13% growth from an adjusted 2026 baseline. That outlook assumes share repurchases offset dilution but does not assume an incremental EPS contribution from buybacks.

Management also expects Health Services adjusted operating income of at least $7B in 2027. It expects 2027 to represent trough earnings for the segment because of 340B pressure and lower Caremark membership, followed by a return to growth.

Balance Sheet, Cash Flow and Capital

CVS generated $15.3B of operating cash flow through the first nine months, compared with $7.2B a year earlier. Stronger earnings, working-capital improvements and payment timing contributed to the increase.

Capital expenditures were $2.4B through September. CVS paid $2.6B in dividends and repaid $4.1B of long-term debt, with no long-term debt issuance during the period.

Cash and cash equivalents ended the quarter at $11.7B, up from $8.5B at year-end 2025. Total debt, including current maturities, was approximately $60.7B, down from approximately $64.6B at year-end.

Management said CVS reached its leverage target ahead of schedule and plans to resume share repurchases in the fourth quarter. The company said its strengthened financial position supports both buybacks and the planned separation, though investors will need more detail on how debt and capital allocation will be divided between the two future companies.

What Investors Should Watch

1. Aetna’s Medicare Advantage margin recovery

The 91.3% third-quarter MBR and substantial increase in Health Care Benefits profit show tangible progress. The key test is whether Aetna can continue improving Medicare profitability in 2027 despite elevated utilization and medical-cost trends.

2. Health Services earnings pressure

Management expects 2027 to be a trough year for Health Services as 340B contribution declines and Caremark faces client membership attrition. Specialty pharmacy growth and health care delivery improvement will need to offset those pressures.

3. Retail pharmacy profit durability

Retail adjusted operating income increased 10.6% despite a 2.0% revenue decline. Investors should watch whether prescription growth, improved reimbursement economics and Rite Aid prescription-file contributions can sustain margin gains amid pharmacy reimbursement pressure.

4. Separation details and commercial agreements

The separation could simplify each business, but CVS must preserve productive ties between Caremark, CVS Pharmacy and Aetna. Future disclosures on debt allocation, tax treatment, one-time costs, leadership structures and commercial agreements will determine the financial credibility of the transaction.

5. Cash-flow quality and capital deployment

Operating cash flow has materially improved, helping CVS resume share repurchases. Investors should monitor whether working-capital gains remain durable and how much capital is directed toward buybacks, debt reduction, dividends and separation preparation.

AlgovestIQ Takeaway

CVS delivered a stronger quarter than its headline revenue growth implies. Aetna’s margin recovery accelerated, retail pharmacy expanded profit despite top-line pressure, and operating cash flow strengthened enough for management to raise guidance and restart buybacks.

The most important operational improvement remains Health Care Benefits. CVS has moved its Medicare Advantage business back into profitability during 2026, according to management, and expects another year of margin expansion in 2027. That is a meaningful change from the Medicare-related cost pressures that had weighed on the company’s earnings profile.

The main unresolved issue is Health Services. CVS still expects at least $7B of adjusted operating income in 2027, but it has now explicitly framed that year as a trough because of 340B pressure and client membership attrition. The ability of specialty pharmacy, purchasing economics and care-delivery improvement to stabilize that business will be central to the longer-term earnings case.

The planned separation adds another layer of opportunity and risk. The two-company structure could allow investors to value the insurance-PBM-care delivery assets separately from the retail pharmacy business. But the financial benefits depend on execution, including capital-structure decisions and commercial arrangements that preserve the operational advantages CVS has built across its businesses.

For now, CVS has improved its earnings base, cash generation and balance-sheet flexibility. The next several quarters should show whether that improvement is durable enough to support both the company’s 2027 earnings targets and a complex separation process without disrupting operations.

How did CVS stock react?

CVS closed at $79.96 on Nov 4, 2026, down 12.5% from $91.41 on Nov 3, 2026, the last close before the results were released.

SessionCloseChange
Nov 3, 2026 (before release)$91.41—
Nov 4, 2026$79.96-12.5%
Nov 5, 2026$81.33-11.0%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: CVS Health Q3 FY2026 earnings call transcript, as of Nov 4, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: CVS Health Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 4, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 4, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.